c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 142 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Foretinib phosphate
CAS:Foretinib phosphate, an oral MET/VEGFR2 inhibitor GSK1363089, may curb tumor growth and spread.Formula:C34H40F2N4O14P2Color and Shape:SolidMolecular weight:828.65S49076 HCl
CAS:S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3.Formula:C22H18ClN3O5Purity:98%Color and Shape:SolidMolecular weight:439.85SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formula:C25H23FN8O2S2·HClPurity:97.95%Color and Shape:SolidMolecular weight:587Ref: TM-T5677
1mg35.00€5mg57.00€10mg95.00€25mg178.00€50mg264.00€100mg374.00€200mg537.00€1mL*10mM (DMSO)96.00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Ref: TM-T6907
1mg34.00€2mg46.00€5mg66.00€10mg92.00€25mg167.00€50mg245.00€100mg356.00€200mg530.00€1mL*10mM (DMSO)82.00€BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Formula:C25H16F2N4O3Purity:98.33%Color and Shape:SolidMolecular weight:458.42Ref: TM-T8326
1mg67.00€2mg88.00€5mg148.00€10mg230.00€25mg430.00€50mg622.00€100mg898.00€1mL*10mM (DMSO)170.00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42Ref: TM-T1963
5mg48.00€10mg63.00€25mg78.00€50mg90.00€100mg124.00€200mg158.00€500mg255.00€1mL*10mM (DMSO)50.00€PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formula:C32H34Cl2N4O4SPurity:97.05% - 98.82%Color and Shape:SolidMolecular weight:641.61CEP-40783
CAS:CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).
Formula:C31H26F2N4O6Purity:99.76% - 99.84%Color and Shape:SolidMolecular weight:588.56Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79Crizotinib
CAS:Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Formula:C21H22Cl2FN5OPurity:99% - 99.87%Color and Shape:SolidMolecular weight:450.34Ref: TM-T1661
2mgTo inquire5mg33.00€10mg49.00€25mg55.00€50mg64.00€100mg88.00€500mg147.00€1mL*10mM (DMSO)50.00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38Ref: TM-T2680
2mg44.00€5mg74.00€10mg97.00€25mg178.00€50mg255.00€100mg359.00€200mg510.00€1mL*10mM (DMSO)84.00€Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2Ref: TM-T25492
1mg35.00€2mg52.00€5mg80.00€10mg119.00€25mg231.00€50mg344.00€100mg480.00€200mg663.00€1mL*10mM (DMSO)92.00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Formula:C25H19ClF2N4O4Purity:98.89% - >99.99%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2699
1mg35.00€5mg79.00€10mg124.00€25mg217.00€50mg359.00€100mg533.00€500mg1,169.00€1mL*10mM (DMSO)92.00€MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formula:C25H21N5O3SPurity:97.16%Color and Shape:SolidMolecular weight:471.53S49076
CAS:S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Formula:C22H22N4O4SPurity:95.35% - 97.4%Color and Shape:SolidMolecular weight:438.5Ref: TM-T3274
1mg34.00€2mg44.00€5mg58.00€10mg93.00€25mg167.00€50mg260.00€100mg432.00€200mg618.00€1mL*10mM (DMSO)64.00€Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormula:C33H37F2N7O4Purity:98.24% - ≥95%Color and Shape:SolidMolecular weight:633.69Ref: TM-T6517
1mgTo inquire2mg46.00€5mg66.00€10mg92.00€25mg149.00€50mg197.00€100mg350.00€1mL*10mM (DMSO)To inquire
